Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Group (AIM:CVSG), the veterinary service provider, will hope the ongoing CMA probe into the industry doesn't overshadow its trading update on Wednesday. Britain's competition authority said in September it was investigating “how veterinary services are bought and sold amid concerns that pet owners may not be getting a good deal.

CVS to meet revenue targets despite looming vet probe, says experts

CVS is holding a highly anticipated investor day on December 5. Previous investor days were a positive catalyst for the stock, although investors are increasingly suspicious following the company's recent guidance cut. CVS's executive team has a lot on their plate, as they lead the company's way to become one of the largest healthcare services companies in the world.

CVS Health: All Eyes On December Investor Day

Target

Walmart

The manufacturer of eye drops sold under CVS Health Corp. CVS, -2.10%, Target Corp. TGT, -0.93%, Rite Aid Corp. RADCQ, +1.70%, Walmart Inc. WMT, -7.48% and other brands has recalled 27 products that were the subject of recent U.S. Food and Drug Administration warnings about potential contamination.

Eye-drop maker recalls CVS, Target, Walmart-branded products

Walgreens

The world of financial markets can be a brutal jungle, filled with dangers at every turn and businesses going bankrupt or turning billionaires almost overnight. Today, some of these risks and uncertain turning points have been assessed to bring you a sensible list of companies that can be termed as value stocks.

3 value stocks you shouldn't let go of this quarter

Johnson & Johnson

CVS Health's guidance cuts are weighing on the stock, but there are good reasons to buy now. Johnson & Johnson still faces legal issues, none of which look likely to derail its long-term goals.

2 Dividend Stocks Near Their 52-Week Lows to Buy and Hold Forever

AllianceBernstein Hld

Arbor Realty Trust

Ares Capital

Alexandria Real Estate Equities

AstraZeneca

BHP Billiton

British American Tobacco

Discover

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

Pfizer

Philip Morris

Vici Properties

March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying dividends.

13 Buyable Inflation-Busting November Dividend Stocks

Apple

AbbVie

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

B&G Foods

Bayerische Motoren Werke AG

BRT Apartments

Blackstone Group

Colgate-Palmolive

Cisco Systems

Dominion Energy

Diversified Healthcare Trust

Disney

S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Interest rates were kept steady again in a range of 5.25% to 5.5%, and it is uncertain if 2023 will see yet another hike. Net investments of around $1,800 in October, primarily targeting the financial sector and high-yielding BDCs.

My Dividend Stock Portfolio: New October Dividend Record - 98 Holdings With 23 Buys

CVS Health (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalue

Is CVS Health Stock Undervalued At $70?

Doximity

Teladoc

Telehealth stocks were all the rage during the pandemic, with many expecting the valuations of these companies to soar due to people staying home and practicing social distancing. However, as the old normal returned, some investors cast doubt over the long-term viability of telehealth stocks.

Top 3 Telehealth Stocks to Invest in for a Future of Virtual Care

Bristol-Myers

Verizon

With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be expected until early Q2 2024, and those stocks trading at elevated valuations stand to lose the most.

High-yield, low-beta value plays for buy-and-hold investors

Archer-Daniels-Midland Company

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

ManpowerGroup

MetLife

Omnicom Group

Southern Company

Exxon Mobil

The Summer, 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff-out the best dividend buys focused on 68 industry leaders using YCharts 11/8/23. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to wholesalers. Three of the 68 are not listed on U.S. exchanges. Their data was excluded. 58 dividend yielding stocks led those 68 industry leaders and ranged 0.19% to 9.56% in annual-yield and ranged -1.29% to 54.34% in broker-estimated one-year price-target-upsides by YCharts 11/8/23 reckoning.

5 Fair-Priced November Fortune 500 Industry-Leader Dogs Out Of 68

Starbucks

T-Mobile US

A dividend growth stock has a much better chance of outperforming the market than a non-payer. A low yield today could become a massive cash cow in just a few years.

3 Excellent Dividend Growth Stocks That Show No Signs of Slowing Down

CVS (CVS) and Walgreens (WBA) shares lost ground Wednesday after IAM Healthcare, a subsection of the International Association of Machinists and Aerospace Workers (IAM), launched The Pharmacy Guild, an effort to unite pharmacy workers who are calling for staffing and workload safety standards.

CVS and Walgreens Shares Fall After Pharmacy Guild Launches With Call to Unionize

The Pharmacy Guild aims to help staff unionize to address what employees have called unsafe working conditions, including at Walgreens and CVS.

Pharmacy walkout organizers help launch national push to unionize pharmacists, technicians

Humana

UnitedHealth Group

Buy-and-hold investing may seem like a boring activity, but it is the path to sustained wealth building. Building positions over time that leverage growth, capital returns, and capital return growth results in accelerating returns and market-beating performance.

3 healthy dividend stocks for buy and hold investors

WOONSOCKET, R.I. , Nov. 7, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) will hold its Investor Day on December 5th, 2023, in Boston, MA.

CVS Health to hold Investor Day on December 5, 2023

Perficient

Tenable Holdings Inc

The market has begun to rebound in recent days due to the U.S. Federal Reserve keeping interest rates steady, signaling the rate hike cycle has possibly come to an end. This is a welcome change since the sharp sell-off that began in late July triggered by inflation fears and the potential impact on elevated rates on economic growth and company earnings.

Don't Get Stuck with These 3 Declining Stocks

News for CVS Health Stock (CVS)